SCHEMBL956090

SCHEMBL956090

Cc1nn2ccccc2c1-c1nc(-c2ccc(F)cc2F)c(C(=O)O)s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RORC P51449 8/20 0.35
CDC7 O00311 2/20 0.35
DBF4 Q9UBU7 2/20 0.35
MAPK14 Q16539 2/20 0.35
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
EGFR P00533 1/20 0.34
RAF1 P04049 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
GSK3B P49841 1/20 0.34
F2RL3 Q96RI0 1/20 0.34
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953770 0.91 CDC7 (0.42) PTGS1PTGS2RAB9ACDC7DBF4
SCHEMBL955904 0.90 CDC7 (0.40) PTGS2RAB9ASMN1; SMN2CDC7DBF4
SCHEMBL952522 0.90 CDC7 (0.39) PTGS1PTGS2RAB9ACDC7DBF4
SCHEMBL955327 0.86 EGFR (0.46) PTGS2RAB9ASMN1; SMN2CDC7DBF4
SCHEMBL955566 0.85 TRPM8 (0.43) SMN1; SMN2CDC7DBF4
SCHEMBL958443 0.85 CDC7 (0.36) SMN1; SMN2RORCCDC7DBF4HTR2C
SCHEMBL953870 0.85 SMN1; SMN2 (0.39) RAB9ASMN1; SMN2RORCCDC7DBF4
SCHEMBL953113 0.82 CDC7 (0.50) RAB9ASMN1; SMN2CDC7DBF4EGFR
SCHEMBL953949 0.82 CDC7 (0.43) SMN1; SMN2RORCCDC7DBF4F2RL3
SCHEMBL951780 0.82 HIF1A (0.39) RAB9ASMN1; SMN2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 PTGS1 1706/4885PTGS2 2116/4885RAB9A 1059/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 PTGS1 123/4885PTGS2 310/4885RAB9A 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.